✦ LIBER ✦

Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study

✍ Scribed by Clifford J Rosen; Marc C Hochberg; Sydney L Bonnick; Michael McClung; Paul Miller; Susan Broy; Risa Kagan; Erluo Chen; Richard A Petruschke; Desmond E Thompson; Anne E de Papp

Book ID: 111485157
Publisher: American Society for Bone and Mineral Research
Year: 2004
Tongue: English
Weight: 243 KB
Volume: 20
Category: Article
ISSN: 0884-0431
DOI: 10.1359/jbmr.040920

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Therapeutic effects of alendronate 35 mg

Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study

✍ Shinji Uchida; Tadaaki Taniguchi; Takafumi Shimizu; Taro Kakikawa; Kotoba Okuyam 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 721 KB

Once-Weekly Risedronate in Men With Oste

Once-Weekly Risedronate in Men With Osteoporosis: Results of a 2-Year, Placebo-Controlled, Double-Blind, Multicenter Study

✍ Steven Boonen; Eric S Orwoll; Dietrich Wenderoth; Karen J Stoner; Rachelle Euseb 📂 Article 📅 2009 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 479 KB

Efficacy and safety of a once-yearly i.v

Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study

✍ Eric S Orwoll; Paul D Miller; Jonathan D Adachi; Jacques Brown; Robert A Adler; 📂 Article 📅 2010 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 216 KB

## Abstract Zoledronic acid (ZOL) has shown beneficial effects on bone turnover and bone mineral density (BMD) in postmenopausal osteoporosis. This study compared the efficacy and safety of a once‐yearly i.v. infusion of ZOL with weekly oral alendronate (ALN) in men with osteoporosis. In this multi

Efficacy and tolerability of once-monthl

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study

✍ Ronald Emkey; Pierre D. Delmas; Michael Bolognese; Joao Lindolfo C. Borges; Feli 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 145 KB

Treatment preference for monthly oral ib

Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II)

✍ Peyman Hadji; Helmut Minne; Michael Pfeifer; Pierre Bourgeois; Patrice Fardellon 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 527 KB

Once-weekly administration of 50 mg etan

Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled trial

✍ Edward C. Keystone; Michael H. Schiff; Joel M. Kremer; Shelly Kafka; Michael Lov 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

## Abstract ## Objective To evaluate the safety, efficacy, and pharmacokinetics of 50 mg etanercept administered subcutaneously once weekly in adult patients with active rheumatoid arthritis (RA). ## Methods Four hundred twenty RA patients were randomized to receive, in a blinded manner, the stu